Table 2.
Protocol for MGIT-DST for PZA R-Mtb with Exo-MS alone and in combination with PZA
| No | Drug | Initial Concentration of the drug preparation | Volume added to MGIT for Test | Final Concentration in MGIT tube except GC | No. of PZA tubes | |
|---|---|---|---|---|---|---|
| GC | PZA R | |||||
| 1 | PZA | 8 mg/mL | 100 μL | 0.1 mg/mL | 1 | 1 |
| 2 | Exo-MS + PZA | 19 mg/mL + 8 mg/mL | 50 μL + 100 μL | 0.125 mg/mL and 0.1 mg/mL | 1 | |
| 3 | Exo-MS + PZA | 19 mg/mL + 8 mg/mL | 100 μL + 100 μL | 0.25 mg/mL and 0.1 mg/mL | 1 | |
| 4 | Exo-MS + PZA | 19 mg/mL + 8 mg/mL | 200 μL + 100 μL | 0.5 mg/mL and 0.1 mg/mL | 1 | |
| 5 | Exo-MS | 19 mg/mL | 50 μL | 0.125 mg/mL and 0.1 mg/mL | 1 | 1 |
| 6 | Exo-MS | 19 mg/mL | 100 μL | 0.25 mg/mL | 1 | |
| 7 | Exo-MS | 19 mg/mL | 200 μL | 0.5 mg/mL | 1 | |
| 8 | Exo-MS+ FeCl3 | 19 mg/mL + 80 mg/mL | 200 μL + 50 μL | 0.5 mg/mL and 0.5 mg/mL | 1 | |